Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XALute phase 3 study of xaluritamig versus cabazitaxel or second androgen receptor-directed therapy in progressive metastatic castration-resistant prostate cancer
NL-OMON58896Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Amgen. Started May 2025; status: active, not recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON58896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58896.